Skip to main content

Zontivity FDA Approval History

FDA Approved: Yes (First approved May 8, 2014)
Brand name: Zontivity
Generic name: vorapaxar
Dosage form: Tablets
Company: Merck
Treatment for: Cardiovascular Risk Reduction

Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist for the prevention of cardiovascular events in high risk patients.

Development timeline for Zontivity

DateArticle
May  8, 2014Approval FDA Approves Zontivity to Reduce the Risk of Heart Attacks and Stroke
Jan 15, 2014Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine
Jul 24, 2013Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine

See also

Zontivity (vorapaxar) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer